Bosh sahifaIPN • EPA
add
Ipsen SA
Yopilish kursi
113,10 €
Kunlik diapazon
111,60 € - 113,40 €
Yillik diapazon
99,70 € - 126,70 €
Bozor kapitalizatsiyasi
9,58 mlrd EUR
Oʻrtacha hajm
55,17 ming
Narx/foyda
13,81
Dividend daromadliligi
1,07%
Asosiy maydon
EPA
Bozor yangiliklari
INTC
2,93%
0,61%
0,48%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(EUR) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 875,90 mln | 7,93% |
Joriy xarajat | 557,05 mln | 8,31% |
Sof foyda | 116,00 mln | 18,85% |
Sof foyda marjasi | 13,24 | 10,06% |
Har bir ulushga tushum | — | — |
EBITDA | 240,85 mln | 0,31% |
Amaldagi soliq stavkasi | 16,30% | — |
Balans
Jami aktivlari
Jami passivlari
(EUR) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 485,40 mln | 17,42% |
Jami aktivlari | 6,55 mlrd | 7,50% |
Jami passivlari | 2,50 mlrd | -6,93% |
Umumiy kapital | 4,05 mlrd | — |
Tarqatilgan aksiyalar | 82,86 mln | — |
Narxi/balansdagi bahosi | 2,32 | — |
Aktivlardan daromad | 6,13% | — |
Kapitaldan daromad | 8,85% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(EUR) | iyn, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 116,00 mln | 18,85% |
Operatsiyalardan naqd pul | 233,00 mln | 8,52% |
Sarmoyadan naqd pul | -99,55 mln | 79,81% |
Moliyadan naqd pul | -159,10 mln | -51,45% |
Naqd pulning sof oʻzgarishi | -26,00 mln | 93,10% |
Boʻsh pul | 15,01 mln | -89,78% |
Haqida
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Ipsen, founded by Henri Beaufour in 1929, has approximately 5000 employees worldwide. Ipsen's medicines are registered in 88 countries with direct commercial presence in over 30 countries. Ipsen has 4 global R&D hubs and 3 pharmaceutical development centers around the world. Ipsen has been a family-owned business for the past 90 years and is publicly traded on the Euronext Paris as part of the SBF 120 index. The Beaufour family owns 57% of its shares and 73% of its voting rights, and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors. Wikipedia
CEO
Tashkil etilgan
1929
Sayt
Xodimlar soni
5 325